Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nanjing Biosion Reports anti-TSLP mAb Effective for Atopic Dermatitis

publication date: Jun 13, 2024

Nanjing Biosion presented positive data from a Phase II proof-of-concept trial of Bosakitug, a high potency anti-TSLP mAb, in subjects with atopic dermatitis. 94% of the patients in the trial had an EASI response of 75% and 25% reported a 100% response. Bosakitug, Biosion’s lead drug candidate, has also started trials for severe asthma and chronic rhinosinusitis with nasal polyps, and it is in preclinical development for COPD. Biosion partnered China rights for Bosakitug with CTTQ and the US rights with Taiwan’s OBI Pharma. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here